Business
AVROBIO to Participate in Four Upcoming Investor Conferences in September
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of
About this update from Tectonic Therapeutic, Inc.
[{"type":"text","content":" CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nAVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in four upcoming investor conferences:\n\nCiti's 17th Annual BioPharma Conference\nDates: Tuesday, Sept. 6, 2022 – Thursday, Sept. 8, 2022\nLocation: Four Seasons Hotel, Boston, Mass\n\n2022 Wells Fargo Healthcare Conference\nDates: Wednesday, Sept. 7, 2022 – Friday, Sept. 9, 2022\nLocation: Encore Boston Harbor, Boston, Mass\n\nH.C. Wainwright 24th Annual Global Investment Conference\nDates: Monday, Sept. 12, 2022 – Wednesday Sept. 14, 2022\nA pre-recorded presentation will be available on the investors section of avrobio.com starting on Monday, Sept. 12 at 7:00 a.m. ET\n\nMorgan Stanley 20th Annual Global Healthcare Conference\nFireside Chat Date: Tuesday, Sept. 13, 2022\nTime: 1:30 p.m. ET\nLocation: Sheraton Hotel, New York, NY\nA live webcast will be made available on the investors section of avrobio.com.\n\nThe webcast events will remain archived on the AVROBIO website for approximately 90 days.\n\nAbout AVROBIO\n\nOur vision is to bring personalized gene therapy to the world. We target the root cause of genetic disease by introducing a functional copy of the affected gene into patients’ own hematopoietic stem cells (HSCs), with the goal to durably express the therapeutic protein throughout the body, including the central nervous system. Our first-in-class pipeline includes clinical programs for cystinosis and Gaucher disease type 1, as well as preclinical programs for Gaucher disease type 3, Hunter syndrome and Pompe disease. Our proprietary plato® gene therapy platform is designed to be scaled to support late-stage clinical development and commercialization globally. We are headquartered in Cambridge, Mass. For additional information, visit avrobio.com and follow us on Twitter and LinkedIn.\n\nForward-Looking Statement\n\nThis press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “aims,” “anticipates,” “believes,” “could,” “designed to,” “estimates,” “expects,” “forecasts,” “goal,” “in...